Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Up on Analyst Upgrade

Capricor Therapeutics, Inc. (NASDAQ:CAPR) shares gapped up prior to trading on Wednesday after JonesTrading upgraded the stock from a hold rating to a buy rating. The stock had previously closed at $8.87, but opened at $9.65. JonesTrading now has a $25.00 price target on the stock. Capricor Therapeutics shares last traded at $9.8020, with a volume of 832,911 shares.

Other analysts also recently issued reports about the stock. Alliance Global Partners downgraded shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 target price for the company. in a research report on Tuesday, July 28th. Ladenburg Thalmann & Co. Inc. cut Capricor Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, July 30th. HC Wainwright downgraded shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, July 27th. Wall Street Zen cut shares of Capricor Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 1st. Finally, Roth Capital downgraded shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 price target for the company. in a report on Monday, July 27th. Five equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $29.77.

Institutional Trading of Capricor Therapeutics

Hedge funds have recently modified their holdings of the company. Bank of America Corp DE increased its position in shares of Capricor Therapeutics by 672.0% during the first quarter. Bank of America Corp DE now owns 415,483 shares of the biotechnology company’s stock valued at $12,631,000 after purchasing an additional 361,664 shares during the period. Montanova Capital LLC increased its holdings in Capricor Therapeutics by 7.2% in the 2nd quarter. Montanova Capital LLC now owns 4,092,784 shares of the biotechnology company’s stock valued at $98,554,000 after buying an additional 274,184 shares during the period. Walleye Capital LLC bought a new stake in Capricor Therapeutics in the 1st quarter valued at $5,397,000. Bank of New York Mellon Corp acquired a new position in shares of Capricor Therapeutics in the 2nd quarter valued at $3,895,000. Finally, Oppenheimer & Co. Inc. raised its stake in shares of Capricor Therapeutics by 169.1% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 203,781 shares of the biotechnology company’s stock valued at $1,930,000 after buying an additional 128,067 shares in the last quarter. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Stock Performance

The business’s 50 day moving average price is $8.10 and its 200-day moving average price is $19.92. The company has a market cap of $595.35 million, a price-to-earnings ratio of -3.88 and a beta of 0.80.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Tuesday, November 10th. The biotechnology company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.29). On average, equities research analysts expect that Capricor Therapeutics, Inc. will post -1.71 earnings per share for the current fiscal year.

Capricor Therapeutics Company Profile

Capricor Therapeutics is a biotechnology company developing cell- and exosome-based therapies for serious diseases. Its research focuses on using these technologies to address conditions with limited treatment options. The company’s leading program is deramiocel, also known as CAP-1002, an investigational therapy made from donor-derived cardiac cells. Capricor is developing it for Duchenne muscular dystrophy, a rare genetic disorder that causes progressive muscle weakness. Capricor is also advancing an exosome-based technology platform for potential therapeutic applications.